Results

1–2 of 2 results for Jared S. Nielsen

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020